CI

At a glance

ClinicalIndex Comparison Record
Phase 1Recruiting· 9 target
Drug / intervention
umbilical cord derived mesenchymal stem cells exosomes (UCMSC-Exo)biological
Likely dose
Not stated in record
Key inclusion· 9
  • ✓Aged 18-60 years
  • ✓AML diagnosed per 2022 WHO criteria, CR1 status, scheduled for consolidation therapy
  • ✓Signed informed consent obtained
  • ✓Estimated survival at least 3 months
Key exclusion· 23
  • ✕CNS manifestations of AML at diagnosis
  • ✕Secondary AML
  • ✕Myelosuppression from causes other than anti-cancer therapy
  • ✕Prior radiation to sternum or pelvis

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06245746
NCT06245746Phase 1RecruitingMonitorUpdated 15mo ago · Completion was 4mo ago
Slow Enrollment
Monitor
CompareCT.gov

A Single-center, Prospective Trial of the Safety and Efficacy of UCMSC-Exo in Consolidation Chemotherapy-induced Myelosuppression in Patients With Acute Myeloid Leukemia After Achieving Complete Remission

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology·interventional·Posted Feb 7, 2024·Updated Mar 21, 2025

In Brief

A Phase 1 clinical trial evaluating umbilical cord derived mesenchymal stem cells exosomes (UCMSC-Exo) for Acute Myeloid Leukemia and 5 related conditions. Currently recruiting, targeting 9 participants across 1 site.

Signals

Enrolling slower than its timeline implies

Detailed Summary

The purpose of the study is to explore the safety and efficacy of UCMSC-Exo in consolidation chemotherapy-induced myelosuppression in patients with acute myeloid leukemia after achieving complete remission.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myeloid Leukemia, Neutropenia, Anemia, Thrombocytopenia, Infections, Bleeding
CountriesChina
Collaborators--

Timeline

Phase 1Recruiting
202520262027
First PostedFeb 7, 2024
Enrollment StartFeb 26, 2025
Primary CompletionFeb 1, 2026
Study CompletionFeb 1, 2027
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 2.4 years ago

Interventions

umbilical cord derived mesenchymal stem cells exosomes (UCMSC-Exo)biological

UCMSC-Exo will be infused intravenously.